AI & Machine Learning in Biotechnology
OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline
Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million.Read More
Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million.Read More